Condition: Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · Sponsor: Immuneering Corporation
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
This description comes directly from the study's public registry record.
Immuneering Study Team · 860-321-1302 · clinicaltrials@immuneering.com
Always discuss trial participation with your own doctor first.
| City of Hope | Phoenix, Arizona, United States | Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| Medical Oncology Hematology Consultants | Newark, Delaware, United States | Recruiting |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie, Florida, United States | Recruiting |
| Florida Cancer Specialists - South | Sarasota, Florida, United States | Recruiting |
| Florida Cancer Specialists - North | St. Petersburg, Florida, United States | Recruiting |
| Florida Cancer Specialists - East | West Palm Beach, Florida, United States | Recruiting |
| Piedmont Healthcare | Atlanta, Georgia, United States | Recruiting |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | Recruiting |
| City of Hope | Chicago, Illinois, United States | Recruiting |
| OSF Medical Center | Peoria, Illinois, United States | Recruiting |
| Maryland Oncology | Columbia, Maryland, United States | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07562152